The Japanese drugmaker said its experimental drug being tested for two epileptic disorders failed to reduce frequency of seizures in patients across late-stage studies.
Tag Archive for: Takeda
Riding the growing wave of interest in molecular glue degraders, Takeda has partnered with Chinese biotech Degron Therapeutics to develop novel therapies for oncology, neuroscience and inflammation.
Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven by increasing generic competition for its ADHD treatment Vyvanse.
Takeda secured another label expansion for the kinase inhibitor, this time in the first-line setting for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
The Japanese drugmaker plans to scale up the production of its dengue vaccine Qdenga through a partnership with Indian vaccine maker Biological E.
On the heels of Takeda’s $300 million licensing deal for rusfertide, Protagonist Therapeutics’ peptide mimetic lowered hematocrit levels in patients with polycythemia vera, a type of blood cancer.
Takeda Pharmaceutical’s therapy for an allergic inflammation of the esophagus has received approval from the U.S. FDA, the Japanese drugmaker said on Monday, capping a years-long regulatory process.
Takeda will launch global Phase III trials of its investigational oral ORX2 agonist TAK-861 in narcolepsy type 1 in the first half of fiscal year 2024 and abandon the candidate’s development in narcolepsy type 2.
Drugmakers including Pfizer, Sanofi, and Takeda Pharmaceutical plan to raise prices in the United States on more than 500 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.
Like the quest to discover a new medicine, pulling off a successful mega-deal is a frustrating and elusive experiment. Tokyo-based drugmaker Takeda understands the difficulty of both. Although boss Christophe Weber will have plenty to celebrate on the upcoming fifth anniversary of his landmark $62 billion Shire acquisition, the deal has delivered no value to his shareholders.